Skip to main content

Table 3 Compliance of antiemetic treatment

From: Cohort study of consistency between the compliance with guidelines for chemotherapy-induced nausea and vomiting and patient outcome

Emetogenisity Actual measure (Early) Actual measure (Delayed) n Compliance
Minimal 5-HT3RA + DEX no 2 Sufficient
5-HT3RA no 1 Sufficient
DEX no 1 Sufficient
no no 3 Sufficient
Low 5-HT3RA + DEX no 29 Sufficient
5-HT3RA + DEX DEX 3 Sufficient
5-HT3RA + DEX D2RA 1 Sufficient
DEX DEX 1 Sufficient
DEX no 3 Sufficient
no no 1 Insufficient
Moderate 5-HT3RA + DEX DEX 6 Sufficient
5-HT3RA + DEX NK1RA + DEX 3 Sufficient
NK1RA + 5-HT3RA + DEX NK1RA 2 Sufficient
NK1RA + 5-HT3RA + steroid (MM) NK1RA 1 Sufficient
NK1RA + 5-HT3RA + DEX 5-HT3RA + DEX + NK1RA 1 Sufficient
5-HT3RA + DEX no 3 Insufficient
5-HT3RA + DEX DEX + D2RA 1 Sufficient
High NK1RA + 5-HT3RA + DEX NK1RA 2 Insufficient
NK1RA + 5-HT3RA + steroid (ML) NK1RA 2 Sufficient
NK1RA + 5-HT3RA + steroid (ML) NK1RA + D2RA 1 Sufficient
5-HT3RA + DEX DEX 2 Insufficient
5-HT3RA + DEX no 1 Insufficient
  1. 5-HT3RA; 5-HT3 receptor antagonist, DEX; Dexamethasone, D2RA; Dopamine receptor D2 receptor antagonist, NK1RA; Neurokinin 1 receptor antagonist, MM; multiple myeloma, ML; malignant lymphoma.